2
|
Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. Int J Radiat Oncol Biol Phys 2018; 102:296-303. [PMID: 30191864 DOI: 10.1016/j.ijrobp.2018.05.040] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Revised: 02/08/2018] [Accepted: 05/16/2018] [Indexed: 10/14/2022]
Abstract
PURPOSE The radiobiology of prostate cancer may favor the extreme hypofractionation inherent in stereotactic body radiation therapy (SBRT); however, data from a large multicenter study are lacking. We therefore examined the hypothesis that dose-escalated SBRT can be safely administered across multiple institutions, with favorable 5-year disease-free survival (DFS) rates compared with historical controls. METHODS AND MATERIALS Twenty-one centers enrolled 309 patients with prostate adenocarcinoma: 172 with low-risk (LR) and 137 with intermediate-risk (IR) disease. All were treated with a non-coplanar robotic SBRT platform using real-time tracking of implanted fiducials. The prostate was prescribed 40 Gy in 5 fractions of 8 Gy. We assessed toxicities using Common Terminology Criteria for Adverse Events (CTCAE) version 3 and biochemical failure using the "nadir + 2" definition. The study population yielded 90% power to identify excessive (>10%) rates of grade ≥3 genitourinary (GU) or gastrointestinal toxicities and, in the LR group, 80% power to show superiority in DFS over a 93% historical comparison rate. RESULTS At a median follow-up of 61 months, 2 LR patients (1.2%) and 2 IR patients (1.5%) experienced grade 3 GU toxicities, far below the 10% toxicity rate deemed excessive (upper limits of 95% confidence interval, 3.5% and 4.3%, respectively). No grade 4 or 5 toxicities occurred. All grade 3 toxicities were GU, occurring 11 to 51 months after treatment. For the entire group, the actuarial 5-year overall survival rate was 95.6% and the DFS rate was 97.1%. The 5-year DFS rate was 97.3% for LR patients (superior to the 93% DFS rate for historical controls; P = .0008; lower limit of 95% confidence interval, 94.6%) and 97.1% for IR patients. CONCLUSIONS Dose-escalated prostate SBRT was administered with minimal toxicity in this multi-institutional study. Relapse rates compared favorably with historical controls. SBRT is a suitable option for LR and IR prostate cancer.
Collapse
|
3
|
Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D'Amico AV, Yu JB. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. J Natl Cancer Inst 2016; 109:2758641. [PMID: 28040795 DOI: 10.1093/jnci/djw281] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 09/26/2016] [Accepted: 10/25/2016] [Indexed: 11/12/2022] Open
Abstract
Background The purpose of this study is to determine the optimal strategy for men with newly diagnosed intermediate-risk prostate cancer by age and cardiac risk. Methods A Markov model was calibrated to the EORTC 22991 trial, which randomly assigned men with intermediate-risk prostate cancer to radiation therapy (RT) with or without six months of hormonal therapy (HT). We compared quality-adjusted life-years (QALYs) in men age 50, 60, and 70 years by age decile and cardiac risk group. Competing risks of cardiovascular mortality were estimated from the published literature. Sensitivity analyses were used to assess the impact of varying model assumptions. Results HT was associated with a net decrease of 0.3 to 0.4 QALYs in men with a history of myocardial infarction. However, for all other men, HT improved QALYs (range = 0.4-2.6 QALYs). Younger men with fewer cardiac risk factors experienced the largest benefit from HT. In sensitivity analyses, the model was only found to be sensitive to the probability of biochemical failure. Men at low risk for biochemical failure (≤8.7% at five years) did not benefit from HT. Further, the benefits of HT did not begin to manifest until after 7.3 years of follow-up. Conclusions The optimal choice of therapy depends upon age, cardiac risk, and disease recurrence risk. Young men with intermediate-risk prostate cancer with no cardiac risk factors benefit most from HT. Men with a history of myocardial infarction who are at very low risk for biochemical failure may be negatively impacted by the addition of HT.
Collapse
Affiliation(s)
- Nataniel H Lester-Coll
- Affiliations of authors: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (NHLC, SJ, WJM, JBY); Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SZG); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA (AVD)
| | - Skyler Johnson
- Affiliations of authors: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (NHLC, SJ, WJM, JBY); Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SZG); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA (AVD)
| | - William J Magnuson
- Affiliations of authors: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (NHLC, SJ, WJM, JBY); Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SZG); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA (AVD)
| | - Samuel Z Goldhaber
- Affiliations of authors: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (NHLC, SJ, WJM, JBY); Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SZG); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA (AVD)
| | - David J Sher
- Affiliations of authors: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (NHLC, SJ, WJM, JBY); Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SZG); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA (AVD)
| | - Anthony V D'Amico
- Affiliations of authors: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (NHLC, SJ, WJM, JBY); Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SZG); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA (AVD)
| | - James B Yu
- Affiliations of authors: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (NHLC, SJ, WJM, JBY); Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SZG); Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX (DJS); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA (AVD)
| |
Collapse
|
5
|
Couñago F, Del Cerro E, Díaz-Gavela AA, Marcos FJ, Recio M, Sanz-Rosa D, Thuissard I, Olaciregui K, Mateo M, Cerezo L. Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy. SPRINGERPLUS 2015; 4:789. [PMID: 26702378 PMCID: PMC4684563 DOI: 10.1186/s40064-015-1596-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Accepted: 12/05/2015] [Indexed: 12/23/2022]
Abstract
To assess and validate the incorporation of the multiparametric magnetic resonance imaging (mpMRI) tumour category (mT-category) to the conventional clinical tumour category (cT-category), in order to guide the radiotherapy (RT) treatment decisions in prostate cancer. In addition, to identify the clinical factors associated to the technique reliability. mpMRI was performed in 274 prostate cancer patients in order to refine the treatment decisions according to PSA, Gleason Score (GS) and cT-category. Comparisons between the cT and mT-category were performed, as well as the impact on the RT treatment [target volume, doses and hormonal therapy (HT)] independently if it was finally performed. Changes in HT indication for intermediate risk were also analyzed. mpMRI validation was performed with pathological staging (n = 90 patients finally decided to join surgery). The mpMRI upstaging range was 86-94 % for any PSA value or GS. Following mpMRI, 32.8 % of the patients (90/274) were assigned to a different risk group. Compared to cT-category, mpMRI identified more intermediate-risk (46.4 vs. 59.5 %) and high-risk (19.0 vs. 28.8 %) prostate cancer patients. This resulted in a higher indication (p < 0.05) of seminal vesicle irradiation (63.5 vs. 70.0 %), inclusion of any extracapsular disease (T3-T4) within the target volume (1.8 vs. 18.2 %), higher doses (65.3 vs. 88.3 %) and HT associated to RT (45.6 vs. 62.4 %). Global accuracy for mpMRI was higher compared to DRE/TRUS (8.9 vs. 71.1 %, p < 0.05). mpMRI reliability was independent of PSA or GS. mpMRI tumor staging significantly modified the RT treatment decisions in all prostate cancer risk groups.
Collapse
Affiliation(s)
- Felipe Couñago
- Department of Radiation Oncology, Hospital Universitario Quiron Madrid, Calle Diego de Velazquez, 1, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Elia Del Cerro
- Department of Radiation Oncology, Hospital Universitario Quiron Madrid, Calle Diego de Velazquez, 1, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Ana Aurora Díaz-Gavela
- Department of Radiation Oncology, Hospital Universitario Quiron Madrid, Calle Diego de Velazquez, 1, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Francisco José Marcos
- Department of Radiation Oncology, Hospital Universitario Quiron Madrid, Calle Diego de Velazquez, 1, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Manuel Recio
- Department of Radiology, Hospital Universitario Quiron, Madrid, Spain
| | - David Sanz-Rosa
- Clinical Department, School of Biomedical Sciences, Universidad Europea, Madrid, Spain
| | - Israel Thuissard
- School of Doctoral Studies and Research, Universidad Europea, Madrid, Spain
| | | | - María Mateo
- Hospital Universitario Quiron, Madrid, Spain
| | - Laura Cerezo
- Departament of Radiation Oncology, Hospital Universitario La Princesa, Madrid, Spain
| |
Collapse
|